Sus Clinicals has filed a notice of an exempt offering of securities to raise $5,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Sus Clinicals is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jeffrey Weedman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Sus Clinicals
Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.
To learn more about Sus Clinicals, visit http://www.susclinicals.com/
Contact:
Jeffrey Weedman, Chief Executive Officer
513-378-8984
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.